The term “immunoglobulin” refers to the breakdown of plasma containing antibodies. IVIg is a blood product that is given intravenously. Contains multivalent IgG antibodies extracted from the plasma of thousands of blood donors.
Individuals who are unable to produce adequate amounts of antibody, such as patients with common variable immunodeficiency, Wiskott-Aldrich syndrome, X-linked agammaglobulinemia and other forms of hypogammaglobulinemia, have adequate levels in the body. Benefit from IVIg to maintain antibodies in.
Get a sample copy of this report at https://www.persistencemarketresearch.com/samples/2830
The global market for IVIg is categorized based on plasma proteins and therapeutic areas. The plasma protein segment is further subdivided into multivalent IVIg, albumin, factor VIII, hyperimmunity (IM & IV), and factor IX. The multivalued IVIg subsegment holds the largest market share in the global IVIg market.
In addition, the therapeutic area segment includes immunodeficiency, autoimmune diseases, and acute infections. The immunodeficiency subsegment is composed of major diseases such as hypogammaglobulinemia (primary immunodeficiency), X-chain agammaglobulinemia, and acquired immunodeficiency (secondary immunodeficiency), and antibody levels. Is low.
The subsegments of autoimmune disease include immune thrombocytopenia (ITP) and inflammatory disease.
Get the table of contents for this report at @ https : //www.persistencemarketresearch.com/toc/2830
Geographically, North America is IVIg’s largest market, followed by Europe and Asia. In North America, the United States is IVIg’s largest market. Europe, Germany, France and the United Kingdom cover the major shares of the IVIg market. Asia is IVIg’s fastest growing market due to the aging population. Older people are more susceptible to antibody deficiency.
Globally, the IVIG market is growing strongly due to an increasing number of patients with bleeding disorders, an increasing senile population, and an increasing number of patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
In addition, increased investment in the healthcare sector is supporting the growth of the IVIg market. In addition, the growing number of patients suffering from autoimmune diseases and other pathological conditions is also supporting the growth of IVIg products on the market.
However, strict regulations hinder the growth of the IVIg market. Some government agencies impose strict guidelines on the proper use of IVIg products. For example, the Canadian Blood Services and the National Advisory Board on Canadian Blood and Blood Products provide practical guidelines for the use of IVIg products in hematologic diseases.
In addition, high treatment costs also hinder the growth of the IVIg market. Some patients cannot afford to buy IVIg products due to the high cost of treatment. IVIg products are very expensive because the materials needed to make them are more expensive and the manufacturing process requires large amounts of blood samples from donors.
Collecting large blood samples is a very complex and tedious process. In addition, the high risk of side effects associated with IVIg treatment also slows the growth of the IVIg market. The main side effects of IVIg treatment include headache, migraine, dizziness, fever, nausea, vomiting, increased heart rate, itching, high blood pressure, coughing and abdominal pain. These side effects prevent many patients from accepting IVIg products.
Get complete report @ https: //www.persistencemarketresearch.com/checkout/2830
Leading companies operating in the IVIg market include Baxter International, Beijing Tiantan Biologics, Biotest AG, China Biological Products, CSL Limited, Gicho Thai Van Biologics and Shanghai RAAS. Blood Products Co., Ltd., Octapharma AG, Grifols, SA, Hualan Biological Engineering Inc., OMRIX Biopharmaceuticals Ltd., and Kedrion SpA